Goldmans slaps buy rating and $16.70 share price target on ResMed Inc. (ASX:RMD)

ResMed Inc. (CHESS) (ASX:RMD) will soon sell its new AirFit F30 CPAP mask.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in ResMed Inc. (CHESS) (ASX: RMD) printed a new record high this morning after the group revealed details over its latest continuous positive airway pressure (CPAP) full face mask the AirFit F30 that it claims is the most advanced mask ever released in its field.

Investors on Wall Street sent the U.S. scrip 2% higher to a record US$114.08 overnight, with the chess depositary instruments (CDIs) traded on the ASX hitting a record $15.89 this morning.

For the Sydney founded but San Francisco headquartered company the CDIs represent a 1/10th interest in the primary U.S. scrip and roughly track their price adjusted for the spot USD/AUD exchange rate.

Today for example the CDIs are equal to the $US114.08 price divided by the spot exchange rate of U.S. 71.9 cents, which equals $A15.87.

Therefore a falling Australian dollar is a benefit for CDI holders alongside the fact that quarterly dividend payments are exchanged from U.S. dollars into Australian dollars at prevailing spot rates.

Notably though ResMed is also a beneficiary of a weaker U.S. dollar as it reports in U.S. dollars, but earns a significant amount of revenue and earnings in Euros or other ex-US dollar currencies.

As such investors shouldn't place too much emphasis on expected currency movements in terms of the investment case.

Analysts at Goldmans value the CDIs at $16.70 based on their positive assessments of its products' competitive position, the public sector reimbursement environment in the U.S, and the company's potential to grow revenues faster than costs over the short term at least.

ResMed stock is up nearly 200% over the past 5 years despite the business facing some headwinds in terms of reimbursement levels in its core U.S. market, a serious tax dispute with the ATO in Australia, and a bitter and costly ongoing legal patent dispute with major rival Fisher & Paykel Healthcare Ltd (ASX: FPH).

Despite all this the group is now worth around $22 billion at almost twice the size of Cochlear Ltd (ASX: COH).

Thanks to ResMed's founder led nature, balance sheet strength and reinvestment in research and development for long term growth it looks to remain a good bet for growth-oriented investors.

However, I would look to dollar cost average into the business over a series of trades over at least a year as it's currently trading on historically high earnings multiples.

Motley Fool contributor Tom Richardson owns shares of Cochlear Ltd. and ResMed Inc. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »